4D Molecular Therapeutics (FDMT)
(Delayed Data from NSDQ)
$5.73 USD
-0.32 (-5.29%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $5.66 -0.07 (-1.22%) 6:14 PM ET
2-Buy of 5 2
D Value F Growth F Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
FDMT 5.73 -0.32(-5.29%)
Will FDMT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for FDMT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for FDMT
4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates
4D Molecular Therapeutics, Inc. (FDMT) Reports Q3 Loss, Lags Revenue Estimates
FDMT: What are Zacks experts saying now?
Zacks Private Portfolio Services
ARS Pharmaceuticals, Inc. (SPRY) Reports Q3 Loss, Misses Revenue Estimates
Heron Therapeutics (HRTX) Reports Q3 Loss, Misses Revenue Estimates
Nektar Therapeutics (NKTR) Reports Q3 Loss, Tops Revenue Estimates
Other News for FDMT
4DMT to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference | FDMT ...
12 Health Care Stocks Moving In Monday's Intraday Session
FDMT Stock: Analyst Chardan Capital Maintains Buy Rating at $25 | FDMT Stock News
12 Health Care Stocks Moving In Friday's Pre-Market Session
Why Apple Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket